Observational studyInternational journal of rheumatic diseases2018

Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

Martin Soubrier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.